Resistant Hypertension, Time‐Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus by Francesca Viazzi, Pamela Piscitelli, Antonio.

Slides:



Advertisements
Similar presentations
Flow diagram showing study population of Chinese patients with type 2 diabetes mellitus and reasons for exclusion Yang X et al. CMAJ 2008;179:
Advertisements

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.
לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Renal Denervation on 24-Hour Ambulatory.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):
Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Sickle Cell Trait With Chronic Kidney.
Date of download: 6/25/2016 From: Blood Pressure and Mortality in U.S. Veterans With Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2013;159(4):
Date of download: 7/1/2016 From: Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2015;162(4):
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Usual Blood Pressure and Risk of New-Onset Diabetes:
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,
Antonio Coca, MD, PhD, FRCP, FESC
Dr John Cox Diabetes in Primary Care Conference Cork
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
The SPRINT Research Group
Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies  Richard.
Copyright © 2015 American Medical Association. All rights reserved.
Blood Pressure and Age in Controlling Hypertension
Copyright © 2011 American Medical Association. All rights reserved.
by Michael D. Elliott, Ajoy Kapoor, Michele A. Parker, Dixon B
Chapter 1: CKD in the General Population
Copyright © 2007 American Medical Association. All rights reserved.
Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.
Associations of renal impairment (adjusted odds ratio and 95% CI) and the presence of individual small vessel disease markers stratified by age. Associations.
Arterioscler Thromb Vasc Biol
Circ Cardiovasc Qual Outcomes
by Clarisse Toledo, George Thomas, Jesse D
The percentage of subjects with de novo development of renal function impairment (GFR
Progress and Promise in RAAS Blockade
Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.
Management of hypertension in patients with chronic kidney disease
Chapter 1: CKD in the General Population
Early Systolic Blood Pressure Changes in Incident Hemodialysis Patients Are Associated with Mortality in the First Year Kidney Blood Press Res 2012;35:663–670.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered.
Volume 79, Issue 12, Pages (June 2011)
Volume 93, Issue 1, Pages (January 2018)
Description of studies for pooled analyses
End point Net change with soy supplements vs control (95% CI) p
Impact of Electronic Acute Kidney Injury (AKI) Alerts With Automated Nephrologist Consultation on Detection and Severity of AKI: A Quality Improvement.
Volume 69, Pages S11-S15 (April 2006)
Yan Xie, Benjamin Bowe, Tingting Li, Hong Xian, Yan Yan, Ziyad Al-Aly 
Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%
Bariatric surgery is associated with improvement in kidney outcomes
Volume 377, Issue 9771, Pages (March 2011)
Volume 76, Issue 6, Pages (September 2009)
Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation?  Pantelis A. Sarafidis, Luis.
(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
Atherosclerotic renovascular disease among hypertensive adults
Volume 82, Issue 7, Pages (October 2012)
Flow chart of the 1683 study members at age 60–64 years by hypertension (HT) status. Flow chart of the 1683 study members at age 60–64 years by hypertension.
Volume 73, Issue 8, Pages (April 2008)
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Volume 76, Issue 6, Pages (September 2009)
Volume 60, Issue 3, Pages (September 2001)
Volume 75, Issue 1, Pages (January 2009)
Associations between type of MI and incident HF
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.
Atrasentan reduces albuminuria in diabetic apoE KO mice.
End point Valsartan Valsartan+HCTZ p
Correlation between change in blood pressure (BP) and a rapid annual decline in kidney function (≥3 mL/min/1.73 m2/year) (logistic regression) (n=7283).
Adjusted HRs for death from any cause and death from specific causes among patients with type 1 diabetes. Adjusted HRs for death from any cause and death.
Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.
Presentation transcript:

Resistant Hypertension, Time‐Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus by Francesca Viazzi, Pamela Piscitelli, Antonio Ceriello, Paola Fioretto, Carlo Giorda, Pietro Guida, Giuseppina Russo, Salvatore De Cosmo, Roberto Pontremoli, and J Am Heart Assoc Volume 6(9):e006745 September 22, 2017 © 2017 Francesca Viazzi et al.

Flow diagram for selection of study patients Flow diagram for selection of study patients. eGFR indicates estimated glomerular filtration rate. Flow diagram for selection of study patients. eGFR indicates estimated glomerular filtration rate. Francesca Viazzi et al. J Am Heart Assoc 2017;6:e006745 © 2017 Francesca Viazzi et al.

Cumulative incidence of renal outcomes in patients with and without aTRH and T2D. Cumulative incidence of renal outcomes in patients with and without aTRH and T2D. ATRH indicates apparent treatment resistant hypertension; CI, confidence interval; eGFR, estimated glomerular filtration rate; T2D, type 2 diabetes mellitus. *P<0.001 vs No‐aTRH. Adjusted odds ratios for eGFR <60 mL/min per 1.73 m2, 1.31 (CI 1.19–1.44; P<0.001), for eGFR reduction >30% from baseline, 1.43 (CI 1.28–1.58; P<0.001), for eGFR <60 or reduction >30% from baseline, 1.30 (CI 1.19–1.42; P<0.001). Francesca Viazzi et al. J Am Heart Assoc 2017;6:e006745 © 2017 Francesca Viazzi et al.

Blood pressure changes during follow‐up. Blood pressure changes during follow‐up. ATRH indicates apparent treatment resistant hypertension; BP, blood pressure; blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure <140/90 mm Hg. Francesca Viazzi et al. J Am Heart Assoc 2017;6:e006745 © 2017 Francesca Viazzi et al.

Mean yearly eGFR slope on the basis of the presence of aTRH and BPC Mean yearly eGFR slope on the basis of the presence of aTRH and BPC. ATRH indicates apparent treatment resistant hypertension; eGFR, estimated glomerular filtration rate; BP, blood pressure control (BPC) refers to the proportion of visits with sys... Mean yearly eGFR slope on the basis of the presence of aTRH and BPC. ATRH indicates apparent treatment resistant hypertension; eGFR, estimated glomerular filtration rate; BP, blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure <140/90 mm Hg. *P<0.01 vs No‐aTRH with BPC; #P<0.01 vs No‐aTRH with NoBPC. Francesca Viazzi et al. J Am Heart Assoc 2017;6:e006745 © 2017 Francesca Viazzi et al.

A, Cumulative incidence of renal end point (eGFR <60) on the basis of albuminuria status and aTRH. A, Cumulative incidence of renal end point (eGFR <60) on the basis of albuminuria status and aTRH. ALB indicates albuminuria; ATRH, apparent treatment resistant hypertension; CI, confidence interval; eGFR, estimated glomerular filtration rate. *Adjusted odds ratios for Alb+/aTRH− vs Alb−/aTRH− 2.00 (CI 1.80–2.23), P<0.001 and #for Alb+/aTRH+ vs Alb−/aTRH+ 1.67 (CI 1.38–2.02), P<0.001. B, Cumulative incidence of renal end point (eGFR <60) on the basis of albuminuria status and time‐updated BPC. ALB indicates albuminuria; BPC, blood pressure control; eGFR, estimated glomerular filtration rate. *Adjusted odds ratios for Alb+/BPC− vs Alb−/BPC− 1.98 (CI 1.79–2.19), P<0.001 and #for Alb+/BPC+ vs Alb−/BPC+ 1.71 (CI 1.34–2.18), P<0.001. Francesca Viazzi et al. J Am Heart Assoc 2017;6:e006745 © 2017 Francesca Viazzi et al.

Odds ratios of reaching renal end point (eGFR <60 mL/min per 1 Odds ratios of reaching renal end point (eGFR <60 mL/min per 1.73 m2) on the basis of time‐updated mean SBP in patients with and without aTRH, taking 140 mm Hg in non aTRH as reference category. Odds ratios of reaching renal end point (eGFR <60 mL/min per 1.73 m2) on the basis of time‐updated mean SBP in patients with and without aTRH, taking 140 mm Hg in non aTRH as reference category. Patients were grouped into 10 mm Hg subsets (ie, those between 136 and 144 in the group labeled 140 and so on). The subset of patients with No‐aTRH and 140 mm Hg SBP was taken as the reference group. ATRH indicates apparent treatment resistant hypertension; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure. Odds ratio for single renal outcome with 95% confidence interval. Francesca Viazzi et al. J Am Heart Assoc 2017;6:e006745 © 2017 Francesca Viazzi et al.